Inhibitors as a therapeutic frontier in lung cancer: Mechanism, opportunities, and molecular docking studies
Explore this paper's citation graph
Summary
This paper explores how molecular inhibitors affect lung cancer cells, examining recent developments and emerging opportunities, and discusses the role of molecular docking studies, which are crucial in drug development as they reveal the molecular interactions and binding affinities between inhibitors and their target proteins.
- Type
- review
- Published
- 2025-08-04
- Cited by
- 2
- References
- 100
- OpenAlex
- https://openalex.org/W4412895834
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:280535711
Keywords
Docking (animal), Mechanism (biology), Lung cancer, Frontier, Computational biology
References
- MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
- Clinical Challenges in Targeting Anaplastic Lymphoma Kinase in Advanced Non-small Cell Lung Cancer
- Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
- Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy
- Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
- Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
- The Molecular Pathology of Lung Cancer.
- Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer.
- Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities.
- Anti-ovarian and anti-breast cancers with dual topoisomerase ii/braf600e inhibitors activities of some substituted indole derivatives
- ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
- Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
- Tumour heterogeneity and resistance to cancer therapies
- High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin.
- The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
- Targeting EGFR in Lung Cancer: Current Standards and Developments
- Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.
- Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors
Cited by
Related papers
- Research on Problems concerning Frontier Control of Southwest Territory
- Frontier Cities: Encounters at the Crossroads of Empire
- The Wild, Wild Web: The Mythic American West and the Electronic Frontier
- Frontier Discourse and China's Maritime Frontier: China's Frontiers and the Encounter with the Sea through Early Imperial History
- The Forgotten Frontier: A History of the Sixteenth-Century Ibero-African Frontier
- Does the Frontier Experience Make America Exceptional
- The Frontier Crimes Regulation and Frontier Governmentality
- The “Kirghiz frontier” and the frontier volosts of the Tomsk Uyezd in the 17th century: formulation of the problem and a review of research☆
- Gunfighter Nation: The Myth of the Frontier in Twentieth-Century America
- From Frontier To Empire: the Concept of the Frontier in Russia, Sixteenth-Eighteenth Centuries